Executive Summary: The "Say No to Nicotine" Initiative
In a high-stakes gathering at the heart of the European Parliament, the European Respiratory Society (ERS), acting on behalf of the European Chronic Disease Alliance, convened a landmark event titled "Say No to Nicotine." The symposium brought together a diverse coalition of Members of the European Parliament (MEPs), senior officials from the World Health Organization (WHO), and leading public health experts to address a singular, urgent challenge: the rapid, unchecked evolution of the nicotine market and its devastating impact on the next generation of Europeans.
As the European Union stands on the precipice of revising its foundational Tobacco Products Directive (TPD), the event served as a clarion call for legislators to abandon reactive policy-making. Instead, experts are urging a proactive, evidence-based approach that closes the loopholes currently being exploited by the tobacco industry to capture young users through flavored vapes, high-dose nicotine pouches, and aggressive digital marketing.
Chronology: A Crisis of Evolution
The landscape of nicotine consumption has shifted dramatically over the last decade. To understand the current regulatory urgency, one must look at the timeline of the industry’s pivot:
- 2014: The current EU Tobacco Products Directive was adopted, focusing primarily on traditional combustible cigarettes and basic e-cigarette guidelines.
- 2018–2022: The emergence of "next-generation products." Tobacco companies, facing declining cigarette sales, aggressively pivoted to e-cigarettes and nicotine pouches, rebranding themselves as "harm reduction" innovators.
- 2023–2024: Public health data began to show a spike in nicotine dependency among adolescents, correlated with the availability of colorful, fruit-flavored, and high-strength nicotine delivery systems.
- Mid-2025 (The Current Moment): The European Commission initiated formal consultations for the revision of the TPD. The "Say No to Nicotine" event was strategically timed to influence these deliberations, ensuring that public health concerns remain at the forefront of the legislative agenda.
Supporting Data: The Rising Tide of Addiction
The arguments presented at the Parliament were not merely rhetorical; they were anchored in an increasingly alarming body of scientific evidence.
The Myth of "Adult-Only" Marketing
While the industry maintains that newer nicotine products are designed as "off-ramps" for lifelong smokers, the data tells a different story. Surveys across multiple EU member states indicate that the uptake of nicotine pouches and vapes is highest among non-smokers, particularly those under the age of 25. The use of sleek, high-tech designs and flavors like "cotton candy" or "tropical fusion" mirrors the historical tactics used by tobacco giants to hook previous generations on combustible cigarettes.
The Toxicity of High-Dose Nicotine
Dr. Daniëlle Cohen of the Leiden University Medical Centre highlighted a critical, often overlooked variable: the concentration of nicotine in modern pouches. These products can deliver a "nicotine hit" far more potent than traditional cigarettes, leading to rapid physiological dependency. For a developing brain, this exposure is particularly detrimental, causing long-term cognitive and behavioral changes.
Regulatory Inconsistencies
One of the most significant challenges identified by the panel is the fragmented nature of current EU law. Because the existing TPD does not explicitly categorize all new nicotine products with the same rigor as tobacco, member states have been left to create a patchwork of regulations. Some countries have banned certain flavors, while others have few restrictions. This lack of a harmonized "EU-wide shield" allows the industry to exploit the weakest links in the regulatory chain.
Official Responses: Voices from the Frontline
The ERS Perspective: A Call for Prevention
Dr. Filippos Filippidis, Chair of the ERS Tobacco Control Committee, set a somber tone for the event. He noted that the tobacco industry’s "transformation" is largely cosmetic. "Young people are being targeted," Dr. Filippidis remarked. "We are at a crucial time for public health in Europe. We know what works; implementing evidence-based policies—such as total bans on flavors, standardized plain packaging, and strict age-verification protocols—can prevent nicotine addiction and save millions of lives."
The WHO’s Call for Leadership
Dr. Angela Ciobanu, representing WHO Europe, underscored the existential nature of the challenge. "The question is no longer whether nicotine and tobacco products are evolving," she stated. "The question is whether public health policies can keep pace. Europe has a unique opportunity to lead, not just in medical innovation, but in legislative protection. We must stop viewing these products as a ‘lesser evil’ and start viewing them for what they are: a vector for lifelong addiction."
Patient Advocacy: The Human Cost
Zena Powell, an ELF Council member and patient representative, brought a necessary human perspective to the legislative debate. Representing those who live with chronic lung conditions, Powell emphasized that the burden of these diseases is not just on the individual, but on the entire healthcare system. "It was encouraging to hear discussions on future-proofing legislation," Powell noted. "The UK’s generational ban—an approach that aims to prevent the sale of tobacco to anyone born after a certain date—stood out as a bold, innovative model that the EU should seriously consider adopting."
Implications: A New Era of Tobacco Control
The Legislative Opportunity
The upcoming revision of the EU Tobacco Products Directive represents the most significant opportunity for tobacco control in a generation. The discussions at the "Say No to Nicotine" event suggest that the goal is no longer just "harm reduction," but "harm prevention." This means shifting the legislative focus from how we help existing smokers quit, to how we ensure the next generation never begins in the first place.
The Role of the European Lung Foundation (ELF)
The ELF’s involvement—through initiatives like FRESHAIR4Life and JA-SAFE—highlights the importance of bridging the gap between clinical research and grassroots advocacy. By ensuring that patient voices, especially those of the youth, are present in the halls of the European Parliament, the ELF is helping to shift the narrative from "industry rights" to "public health rights."
A Future-Proofed Strategy
To effectively address the challenges of the next decade, participants argued that the new EU directive must be "future-proofed." This involves:
- Broad Definitions: Updating regulations to cover any product containing nicotine, regardless of whether it is derived from tobacco or synthetic sources.
- Harmonization: Establishing a baseline of strict rules across all 27 member states to prevent "forum shopping" by tobacco companies looking for lax jurisdictions.
- Digital Vigilance: Implementing stricter controls on the marketing of nicotine products on social media platforms, where the vast majority of youth recruitment occurs.
Conclusion: A Mandate for Action
The "Say No to Nicotine" event was more than a series of presentations; it was a rallying point for a Europe that refuses to be defined by the commercial interests of the tobacco industry. The consensus among the experts was clear: the status quo is failing. As the European Commission moves forward with the TPD revision, the voices of the medical community, patient advocates, and public health officials have created a powerful mandate for change.
The path ahead will be difficult, marked by intense lobbying from industry stakeholders who benefit from the status quo. However, the stakes—the long-term health, respiratory capacity, and freedom from addiction for millions of young Europeans—make this a battle that the European Union cannot afford to lose. By acting now, the EU can secure a healthier, nicotine-free future for its citizens, proving that public health policy can, and must, stay ahead of the curve.
For Further Information
- The ERS Perspective: Say no to nicotine – ERS
- Youth Advocacy: Youth Group – European Lung Foundation
- Regulatory Frameworks: Product regulation – European Commission
